Caliber Therapeutics

About:

Caliber Therapeutics offers Targeted Angioplasty Drug Delivery balloon, a stent-free delivery platform of anti-restenotic drugs.

Website: http://www.calibertherapeutics.com

Top Investors: SternAegis

Description:

Caliber Therapeutics, Inc. engages in the development and commercialization of minimally-invasive balloon-based drug delivery products for the intervention of atherosclerotic diseases. It offers Targeted Angioplasty Drug Delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices.

Total Funding Amount:

$12M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New Hope, Pennsylvania, United States

Founded Date:

2005-01-01

Founders:

Bill Baumbach, David Hochman

Number of Employees:

11-50

Last Funding Date:

2017-06-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai